REGN9933

Phase 3Small molecule

Regeneron

REGN9933 is one of 60 small molecule programs targeting Atrial Fibrillation. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrial FibrillationActive, not recruiting

Peripheral Artery DiseaseActive, not recruiting

Atrial Fibrillation (AF)Recruiting

Venous Thromboembolism (VTE)Not yet recruiting

Peripheral Artery Disease (PAD)Recruiting

Atrial FibrillationPhase 2

Active, not recruiting

Peripheral Artery DiseasePhase 3

Active, not recruiting

Atrial Fibrillation (AF)Phase 3

Recruiting

Venous Thromboembolism (VTE)Phase 3

Not yet recruiting

Peripheral Artery Disease (PAD)Phase 3

Recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

REGN9933

Regeneron

Phase 3

8 2

Calquence

AstraZeneca

Preclinical

1 3

Calan

VVal Adams

Preclinical

4 4

Brukinsa

BBeOne Medicines

Preclinical

1 5

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 7

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 8

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 9

Direct Anticoagulant

Bayer

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Atrial Fibrillation (AF)

NCT07175428

Q2 2029

Phase 3Recruiting

Atrial Fibrillation (AF)

NCT07430956

Q3 2029

Phase 3Not yet recruiting

Venous Thromboembolism (VTE)

NCT07697599

Q4 2029

Phase 3Recruiting

Peripheral Artery Disease (PAD)

NCT07318610

Clinical

Trials by Indication[1]

Atrial Fibrillation (AF)2 trials

A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS)

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT07175428·1,200 enrolled

A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, Versus Placebo in Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07430956·2,628 enrolled

Catheter1 trial

A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)

Active, not recruiting· Regeneron logo

Regeneron·Phase 2·NCT06299111·195 enrolled

Gastrointestinal1 trial

Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants

Completed· Regeneron logo

Regeneron·Phase 1·NCT06444178·224 enrolled

Adult1 trial

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers

Completed· Regeneron logo

Regeneron·Phase 1·NCT05102136·56 enrolled

Knee Replacement Surgery1 trial

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Completed· Regeneron logo

Regeneron·Phase 2·NCT05618808·373 enrolled

2 more indications

Venous Thromboembolism (VTE)1 trial

A Master Protocol for a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, for Prophylaxis of Venous Thromboembolism in Participants With a Peripherally Inserted Central Catheter (PICC) (ROXI-PEAK)

Not yet recruiting· Regeneron logo

Regeneron·Phase 3·NCT07697599·1,908 enrolled

Peripheral Artery Disease (PAD)1 trial

A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants With Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07318610·7,050 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for REGN9933. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN9933 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN9933. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Regeneron

REGN9933

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2029

Q3 2029

Q4 2029

Trials by Indication[1]

Atrial Fibrillation (AF)2 trials

Catheter1 trial

Gastrointestinal1 trial

Adult1 trial

Knee Replacement Surgery1 trial

Venous Thromboembolism (VTE)1 trial

Peripheral Artery Disease (PAD)1 trial

References

Drug Info

Quick Facts

Related News